Nomura Asset Management Co. Ltd. Trims Stake in Natera, Inc. $NTRA

Nomura Asset Management Co. Ltd. lowered its position in Natera, Inc. (NASDAQ:NTRA) by 2.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 218,195 shares of the medical research company’s stock after selling 4,895 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Natera were worth $49,986,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Horizon Investments LLC purchased a new stake in shares of Natera in the third quarter valued at $32,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Natera in the fourth quarter valued at $41,000. Sound Income Strategies LLC raised its stake in shares of Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 45 shares during the period. TD Waterhouse Canada Inc. purchased a new stake in shares of Natera in the fourth quarter valued at $62,000. Finally, AXS Investments LLC purchased a new stake in shares of Natera in the third quarter valued at $69,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Activity

In other news, insider Solomon Moshkevich sold 1,652 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $202.84, for a total value of $335,091.68. Following the sale, the insider directly owned 140,643 shares in the company, valued at approximately $28,528,026.12. This trade represents a 1.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 902 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $206.16, for a total transaction of $185,956.32. Following the completion of the sale, the chief executive officer owned 149,867 shares in the company, valued at $30,896,580.72. This represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 34,406 shares of company stock valued at $6,984,955 over the last 90 days. 5.05% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on NTRA. JPMorgan Chase & Co. increased their target price on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. William Blair assumed coverage on shares of Natera in a report on Tuesday, April 14th. They issued an “outperform” rating on the stock. BTIG Research cut their price target on shares of Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Finally, Wells Fargo & Company upped their price target on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $256.60.

Natera Price Performance

Shares of Natera stock opened at $223.37 on Monday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The firm’s 50-day moving average is $202.37 and its two-hundred day moving average is $215.75. The stock has a market cap of $31.99 billion, a price-to-earnings ratio of -137.04 and a beta of 1.56.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.05% and a negative return on equity of 14.74%. The business had revenue of $665.50 million for the quarter, compared to analysts’ expectations of $600.68 million. During the same period last year, the business earned ($0.41) EPS. On average, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.